Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat tumors and viruses [3] - The company's lead program, Annamycin, is a next-generation anthracycline aimed at avoiding multidrug resistance and reducing cardiotoxicity associated with current treatments [3] Financial Results Announcement - Moleculin will report its financial results for the quarter ended September 30, 2024, on November 8, 2024 [1] - A conference call and live audio webcast will be held on November 11, 2024, at 8:30 AM ET to discuss these results [1][2] Clinical Trials and Development - The company is initiating the MIRACLE Trial (MB108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML) [4] - Following a successful Phase 1B/2 study, Moleculin believes it has reduced the risks associated with the development pathway for Annamycin's approval [4] Additional Drug Development - Moleculin is also developing WP1066, an immune/transcription modulator targeting brain tumors and pancreatic cancers [5] - The company is working on a portfolio of antimetabolites, including WP1122, for potential treatment of pathogenic viruses and certain cancer indications [5]
Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast